170 related articles for article (PubMed ID: 34593153)
1. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma.
Roberts SK; Majeed A; Kemp W
Clin Liver Dis; 2021 Nov; 25(4):785-803. PubMed ID: 34593153
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response.
Na JE; Sinn DH; Lee JH; Jang HJ; Baek SY; Kim KA; Kang WS; Gwak GY; Paik YH; Kim YJ; Choi MS; Yoon JH; Lee JH; Koh KC; Paik SW
J Viral Hepat; 2021 Oct; 28(10):1392-1399. PubMed ID: 34251707
[TBL] [Abstract][Full Text] [Related]
4. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Bahadır Ö; Özdil K; Doğanay HL
J Viral Hepat; 2021 May; 28(5):826-836. PubMed ID: 33586270
[TBL] [Abstract][Full Text] [Related]
5. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B.
Yip TC; Wong GL; Wong VW; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Chan HL
J Hepatol; 2020 May; 72(5):847-854. PubMed ID: 31857194
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
7. No Difference in Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection Treated With Entecavir vs Tenofovir.
Oh H; Yoon EL; Jun DW; Ahn SB; Lee HY; Jeong JY; Kim HS; Jeong SW; Kim SE; Shim JJ; Sohn JH; Cho YK;
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2793-2802.e6. PubMed ID: 32135246
[TBL] [Abstract][Full Text] [Related]
8. Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea.
Choi H; Seo GH
J Korean Med Sci; 2021 Apr; 36(14):e89. PubMed ID: 33847080
[TBL] [Abstract][Full Text] [Related]
9. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
10. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir.
Hsu YC; Ho HJ; Lee TY; Huang YT; Wu MS; Lin JT; Wu CY; El-Serag HB
J Viral Hepat; 2018 May; 25(5):543-551. PubMed ID: 29193536
[TBL] [Abstract][Full Text] [Related]
11. [Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].
Zhao Z; Wang KF; Chen L; You QH; Wu YY; Sun J
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):344-349. PubMed ID: 33979961
[No Abstract] [Full Text] [Related]
12. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
13. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma.
Lee SW; Choi J; Kim SU; Lim YS
Clin Mol Hepatol; 2021 Jul; 27(3):402-412. PubMed ID: 34157830
[TBL] [Abstract][Full Text] [Related]
14. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study.
Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS
JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080
[TBL] [Abstract][Full Text] [Related]
15. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
[TBL] [Abstract][Full Text] [Related]
16. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir.
Chang JW; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Seo YS; Lee HA; Kim MN; Lee YR; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Park SY; Kim SU
J Viral Hepat; 2021 Jan; 28(1):95-104. PubMed ID: 33029863
[TBL] [Abstract][Full Text] [Related]
17. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
Lee SW; Kwon JH; Lee HL; Yoo SH; Nam HC; Sung PS; Nam SW; Bae SH; Choi JY; Yoon SK; Han NI; Jang JW
Gut; 2020 Jul; 69(7):1301-1308. PubMed ID: 31672838
[TBL] [Abstract][Full Text] [Related]
18. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.
Coffin CS; Rezaeeaval M; Pang JX; Alcantara L; Klein P; Burak KW; Myers RP
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1262-9. PubMed ID: 25312649
[TBL] [Abstract][Full Text] [Related]
19. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.
Papatheodoridis GV; Chan HL; Hansen BE; Janssen HL; Lampertico P
J Hepatol; 2015 Apr; 62(4):956-67. PubMed ID: 25595883
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma.
Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M
Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]